Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
INDV filed an amended Form 144 reporting intended dispositions totaling 36,000 shares through Fidelity Brokerage Services LLC on 06/08/2026. The filing lists three prior restricted stock vesting entries of 6,478, 6,247, and 23,275 shares dated 11/28/2021, 03/05/2022, and 03/09/2023, respectively. The document shows an aggregate value figure of $1,357,200.00 and references NASDAQ in the record.
INDV submitted a Form 144 notice listing the proposed sale of 36,000 shares of Common Stock. The filing shows an aggregate figure of $1,357,200.00 and a reference figure of 121,922,058 with the date 06/08/2026. The filing also lists prior restricted stock vesting entries of 6,478, 6,247 and 23,275 shares dated 11/28/2021, 03/05/2022 and 03/09/2023 respectively.
Indivior Pharmaceuticals, Inc. filed an update on management and shareholder voting. Effective June 1, 2026, the company will eliminate the Chief Scientific Officer role. Dr. Christian Heidbreder will move to an advisory role through the end of 2026, with his December 31, 2026 termination treated as a termination without cause under his employment agreement.
The filing also reports results of the May 13, 2026 virtual annual shareholder meeting. Stockholders elected eight directors, approved executive compensation on an advisory basis, chose an annual “say‑on‑pay” vote schedule, and ratified PricewaterhouseCoopers LLP US as independent auditor for the fiscal year ending December 31, 2026.
Madison Avenue International LP and affiliated reporting persons report beneficial ownership of 4,315,162 shares of Indivior Pharmaceuticals common stock as of March 31, 2026. The filing states this equals approximately 3.5% of the class based on 121,922,058 shares outstanding as of March 18, 2026.
The group structure disclosed names Madison Avenue Partners, EMAI Management, Madison Avenue GP, Caraway Jackson Investments LLC, and Eli Samaha, each described with shared voting and dispositive power over the 4,315,162 shares.
Indivior Pharmaceuticals director Juliet Thompson reported routine equity compensation and related tax withholding transactions. She received a grant of 6,518 Restricted Stock Units, each representing one share of common stock, which will vest immediately before the next annual stockholder meeting if she continues serving the company.
To satisfy tax withholding obligations from RSU vesting on May 12, 2026, 1,117 shares of common stock were withheld at a price of $38.28 per share, which is not an open-market sale. After these transactions, Thompson holds 12,973 shares directly and 5,775 shares indirectly through her spouse.
Humphreys Keith reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Keith Humphreys reported a compensation-related equity grant. He received 6,518 shares of Common Stock in the form of Restricted Stock Units, with no cash price per share shown in the filing. After this award, he directly holds 16,042 shares of the company’s stock. The RSUs vest on the day immediately before the next annual stockholder meeting following the grant date, as long as he continues serving the company until that vesting date.
Kingsley Stuart A reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Stuart A. Kingsley received an equity award of 6,518 shares of common stock in the form of restricted stock units. These RSUs were granted at $0.00 per share as compensation, not through an open-market purchase.
Each RSU represents a right to receive one share of common stock and will vest on the day immediately before the next annual stockholder meeting following the grant date, if Kingsley continues serving the company. After this award, he holds 12,100 shares of Indivior common stock directly.
Indivior Pharmaceuticals, Inc. reported that director Daniel A. Ninivaggi acquired 6,518 shares of common stock through a grant of Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of common stock at vesting.
The RSUs vest on the day immediately preceding the company’s next annual stockholder meeting, subject to his continued service. Following this equity award, Ninivaggi directly owns 27,163 shares of Indivior common stock, reflecting a routine compensation-related increase in his holdings rather than an open‑market purchase.
Ryan Barbara reported acquisition or exercise transactions in this Form 4 filing.
Indivior Pharmaceuticals, Inc. director Ryan Barbara reported receiving a grant of 6,518 shares of common stock in the form of Restricted Stock Units (RSUs) at no cash cost. After this award, the director holds 12,242 common shares directly.
Each RSU represents a contingent right to receive one share of common stock and will vest on the day immediately before the next annual stockholder meeting, as long as the director continues to serve until that date. This is a compensation-related equity award rather than an open‑market purchase or sale.